HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1D Dilated Cardiomyopathy

mutation in cardiac troponin T

Also Known As:

Cardiomyopathy, Dilated, 1D; CMD1D

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Cardiovascular Diseases: 91362
- Heart Diseases: 26014
  - Cardiomyopathies: 19128
    - Dilated Cardiomyopathy: 8213
      - 1D Dilated Cardiomyopathy: 3
  - Cardiomegaly: 10139
    - Dilated Cardiomyopathy: 8213
      - 1D Dilated Cardiomyopathy: 3
Congenital, Hereditary, and Neonatal Diseases and Abnormalities: 933
- Inborn Genetic Diseases: 11939
  - Laminopathies: 484
    - Dilated Cardiomyopathy: 8213
      - 1D Dilated Cardiomyopathy: 3

Related Diseases

1.	Cognitive Dysfunction
2.	Muscular Dystrophies (Muscular Dystrophy)
3.	Walker-Warburg Syndrome
4.	Encephalitis (Encephalitis, Rasmussen)
5.	1C Dilated Cardiomyopathy

Experts

1.	Comim, Clarissa M: 2 articles (01/2017 - 01/2016)
2.	Schactae, Aryadnne L: 2 articles (01/2017 - 01/2016)
3.	Vainzof, Mariz: 2 articles (01/2017 - 01/2016)
4.	Barichello, Tatiana: 1 article (01/2017)
5.	Dal-Pizzol, Felipe: 1 article (01/2017)
6.	Generoso, Jaqueline S: 1 article (01/2017)
7.	Michels, Monique: 1 article (01/2017)
8.	Palmas, Daphne: 1 article (01/2017)
9.	Dominguini, Diogo: 1 article (01/2016)
10.	Freiberger, Viviane: 1 article (01/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to 1D Dilated Cardiomyopathy:

1.	Dystroglycans (Dystroglycan)IBA 01/01/2017 - "Congenital Muscular Dystrophy type 1D (CMD1D) is characterized by an abnormal glycosylation of α-DG (α-dystroglycan) and is associated to the central nervous system (CNS) abnormalities such as cognitive impairment. " 01/01/2016 - "Congenital muscular dystrophies 1D (CMD1D) present a mutation on the LARGE gene and are characterized by an abnormal glycosylation of α-dystroglycan (α-DG), strongly implicated as having a causative role in the development of central nervous system abnormalities such as cognitive impairment seen in patients. " 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "
2.	Matrix Metalloproteinases (MMPs)IBA 01/01/2017 - "The purpose of the research was to evaluate the blood-brain barrier permeability (BBB) permeability and matrix metalloproteinases (MMP) -2 and -9 in adult Largemyd-/- mice in order to understand the physiopathology of brain involvement during the CMD1D process. " 01/01/2017 - "Our results suggest that the pathophysiologic processes can be associated to the action of MMPs and BBB disruption and that the BBB breakdown is relevant to the perpetuation of brain inflammation and can be related to brain dysfunction observed in CMD1D patients."
3.	DystrophinIBA 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "
4.	IntegrinsIBA 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "
5.	Laminin (Merosin)IBA 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "
6.	Glycoproteins (Glycoprotein)IBA 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "
7.	CollagenIBA 03/01/2009 - "We initially present the main clinical and diagnostic data concerning the CMDs related to changes in the complex dystrophin-associated glycoproteins-extracellular matrix: CMD with merosin deficiency (CMD1A), collagen VI related CMDs (Ullrich CMD and Bethlem myopathy), CMDs with abnormal glycosylation of alpha-dystroglycan (Fukuyama CMD, Muscle-eye-brain disease, Walker-Warburg syndrome, CMD1C, CMD1D), and the much rarer CMD with integrin deficiency. "